• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·MVMD.CN
Share

Mountain Valley MD Holdings Inc. Stocks

CA$ 0.08Last Updated 28.07.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

CA$ 18.75M

CA$ 0.08
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Mountain Valley MD Holdings Inc., operating through its subsidiary Mountain Valley MD Inc., functions as a health and wellness enterprise. The company focuses on deploying and licensing its proprietary innovations to external entities within the pharmaceutical, vaccine, and nutritional supplement sectors. Its portfolio encompasses Quicksome, an advanced technology for oral drug formulation and delivery; Quicksol, designed for enhancing solubility; and a dose-sparing adjuvant. Additionally, the firm is actively developing IM032, a compound currently being evaluated in male beagle dogs to assess intramuscular versus subcutaneous administration methods. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 16:50

Shares of the micro-cap biotech company Processa plummeted following the announcement of a merger. What went wrong?

30.07.2026 16:15

Opinion: The AI Boom vs. the Dot-Com Era. What Are Their Main Differences?

30.07.2026 15:50

July Could Be the Worst Month for Chinese Stocks in 10 Years

30.07.2026 15:40

Morning in New York: Focus on Inflation Data, New Reports from Big Tech, and Geopolitics

30.07.2026 15:00

IPO Reformation: The Brand That Dressed Taylor Swift and Jennifer Aniston Goes Public

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026